Ofatumumab versus Teriflunomide in Multiple Sclerosis

L. Hauser, Stephen; Bar‐Or, Amit; Cohen, Jeffrey; Comı, Gıancarlo; Correale, Jorge; K. Coyle, Patricia; H. Cross, Anne; Sèze, de; Leppert, David; Montalbán, Xavier; Selmaj, Krzysztof; Wiendl, Heinz; Kerloëguen, Cécile; Willi, Roman; Li, Bingbing; Kakarieka, Algirdas; Tomic, Davorka; Goodyear, Alexandra; Pingili, Ratnakar; A. Häring, Dieter; Ramanathan, Krishnan; Merschhemke, Martin; Kappos, Ludwig

doi:10.1056/nejmoa1917246

Public

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Published in New England Journal of Medicine • Aug 5, 2020

Authors:

Stephen L. Hauser

Amit Bar‐Or

Jeffrey Cohen

Abstract

BACKGROUND: Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known. METHODS: In t...

Subject

Teriflunomide

Ofatumumab

Multiple sclerosis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!